| Demonstrating in-cell target engagement using a pirin protein degradation probe (CCT367766) NEA Chessum, SY Sharp, JJ Caldwell, AE Pasqua, B Wilding, ... Journal of medicinal chemistry 61 (3), 918-933, 2018 | 98 | 2018 |
| Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen Journal of Medicinal Chemistry 60 (1), 180-201, 2017 | 58 | 2017 |
| Nitrile reductase from Geobacillus kaustophilus: a potential catalyst for a new nitrile biotransformation reaction B Wilding, M Winkler, B Petschacher, R Kratzer, A Glieder, N Klempier Advanced Synthesis & Catalysis 354 (11‐12), 2191-2198, 2012 | 38 | 2012 |
| Targeting the Substrate Binding Site of E. coli Nitrile Reductase QueF by Modeling, Substrate and Enzyme Engineering B Wilding, M Winkler, B Petschacher, R Kratzer, S Egger, G Steinkellner, ... Chemistry–A European Journal 19 (22), 7007-7012, 2013 | 31 | 2013 |
| Newest Developments in the Preparation of Thieno[2,3-d]pyrimidines B Wilding, N Klempier Organic Preparations and Procedures International 49 (3), 183-215, 2017 | 27 | 2017 |
| Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling B Wilding, D Scharn, D Boese, A Baum, V Santoro, P Chetta, R Schnitzer, ... Nature Cancer 3 (7), 821-836, 2022 | 22 | 2022 |
| Chemoenzymatic one-pot reaction from carboxylic acid to nitrile via oxime M Horvat, V Weilch, R Rädisch, S Hecko, A Schiefer, F Rudroff, B Wilding, ... Catalysis Science & Technology 12 (1), 62-66, 2022 | 21 | 2022 |
| Privileged structures and polypharmacology within and between protein families J Meyers, NEA Chessum, S Ali, NY Mok, B Wilding, AE Pasqua, ... ACS Medicinal Chemistry Letters 9 (12), 1199-1204, 2018 | 21 | 2018 |
| An investigation of nitrile transforming enzymes in the chemo-enzymatic synthesis of the taxol sidechain B Wilding, AB Veselá, JJB Perry, GW Black, M Zhang, L Martínková, ... Organic & biomolecular chemistry 13 (28), 7803-7812, 2015 | 21 | 2015 |
| HSF1 pathway inhibitor clinical candidate (CCT361814/NXP800) developed from a phenotypic screen as a potential treatment for refractory ovarian cancer and other malignancies AE Pasqua, SY Sharp, NEA Chessum, A Hayes, L Pellegrino, MJ Tucker, ... Journal of Medicinal Chemistry 66 (8), 5907-5936, 2023 | 17 | 2023 |
| A practical synthesis of 5-functionalized thieno [2, 3-d] pyrimidines B Wilding, S Faschauner, N Klempier Tetrahedron letters 56 (30), 4486-4489, 2015 | 17 | 2015 |
| The Nitrile‐Forming Enzyme 7‐Cyano‐7‐Deazaguanine Synthase from Geobacillus kaustophilus: A Reverse Nitrilase? M Winkler, K Dokulil, H Weber, T Pavkov‐Keller, B Wilding ChemBioChem 16 (16), 2373-2378, 2015 | 11 | 2015 |
| Kinetic analysis and probing with substrate analogues of the reaction pathway of the nitrile reductase QueF from Escherichia coli J Jung, T Czabany, B Wilding, N Klempier, B Nidetzky Journal of Biological Chemistry 291 (49), 25411-25426, 2016 | 10 | 2016 |
| Targeting protein synthesis, folding, and degradation pathways in cancer AE Pasqua, B Wilding, MD Cheeseman, K Jones Elsevier, 2017 | 9 | 2017 |
| Abstract A085: BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in preclinical … A Tedeschi, L Herdeis, V Santoro, F Savarese, B Wilding, M Treu, J Fuchs, ... Molecular Cancer Therapeutics 22 (12_Supplement), A085-A085, 2023 | 7 | 2023 |
| A convenient synthetic route to substituted pyrrolo [2, 3-b] pyridines via a novel ethylene-bridged compound B Wilding, C Vidovic, N Klempier Tetrahedron letters 56 (47), 6606-6609, 2015 | 7 | 2015 |
| Investigating the phosphinic acid tripeptide mimetic DG013A as a tool compound inhibitor of the M1-aminopeptidase ERAP1 B Wilding, AE Pasqua, NEA Chessum, OA Pierrat, T Hahner, K Tomlin, ... Bioorganic & Medicinal Chemistry Letters 42, 128050, 2021 | 4 | 2021 |
| Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity K Jones, M Cheeseman, N Chessum, E Pasqua, L Evans, M Tucker, ... US Patent 10,647,678, 2020 | 4 | 2020 |
| Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer J Broeker, J Abbott, CUI Jianwen, SW Fesik, J Fuchs, A Gollner, L Herdeis, ... US Patent App. 18/060,053, 2023 | 3 | 2023 |
| Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers B Wilding, L Woelflingseder, A Baum, K Chylinski, G Vainorius, N Gibson, ... Cancer Discovery 15 (1), 119-138, 2025 | 2 | 2025 |
